Abstract
From the first description of its anatomy by T. Willis to the novel therapeutic manipulations, it is unanimously recognized that the sympathetic nervous system (SNS) holds a crucial role in cardiovascular homeostasis. The introduction of sophisticated techniques, as microneurography and regional norepinephrine spillover provided the evidence for the role of sympathetic overactivity in various cardiovascular disease entities. Sympathetic activation is common in patients with essential hypertension and contributes to initiation, maintenance and progression of the disease and it contributes to the manifestation of its major complications. A considerable body of evidence relates SNS overactivity with high sodium intake in experimental animals and humans and the underlying mechanisms have nowadays been elucidated. SNS activity is more pronounced in patients with resistant hypertension and there are several conditions that lead to this phenomenon, as older age, kidney disease, obesity and metabolic syndrome, mental stress and sleep apnea. SNS overactivity holds also a key physiopathological role in heart failure, acute coronary syndromes and arrhythmias. Moreover, inhibition of sympathetic overactivity by various means, including central SNS suppressing drugs, peripheral alpha- and beta- adrenergic receptor blockers, or novel approaches as renal sympathetic denervation have been used successfully in the treatment of all these disorders.
Keywords: Sympathetic nervous system, sympathetic overactivity, microneurography, noradrenaline spillover, hypertension.
Current Vascular Pharmacology
Title:Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Volume: 12 Issue: 1
Author(s): Manolis A.J., Poulimenos L.E., Kallistratos M.S., Gavras I. and Gavras H.
Affiliation:
Keywords: Sympathetic nervous system, sympathetic overactivity, microneurography, noradrenaline spillover, hypertension.
Abstract: From the first description of its anatomy by T. Willis to the novel therapeutic manipulations, it is unanimously recognized that the sympathetic nervous system (SNS) holds a crucial role in cardiovascular homeostasis. The introduction of sophisticated techniques, as microneurography and regional norepinephrine spillover provided the evidence for the role of sympathetic overactivity in various cardiovascular disease entities. Sympathetic activation is common in patients with essential hypertension and contributes to initiation, maintenance and progression of the disease and it contributes to the manifestation of its major complications. A considerable body of evidence relates SNS overactivity with high sodium intake in experimental animals and humans and the underlying mechanisms have nowadays been elucidated. SNS activity is more pronounced in patients with resistant hypertension and there are several conditions that lead to this phenomenon, as older age, kidney disease, obesity and metabolic syndrome, mental stress and sleep apnea. SNS overactivity holds also a key physiopathological role in heart failure, acute coronary syndromes and arrhythmias. Moreover, inhibition of sympathetic overactivity by various means, including central SNS suppressing drugs, peripheral alpha- and beta- adrenergic receptor blockers, or novel approaches as renal sympathetic denervation have been used successfully in the treatment of all these disorders.
Export Options
About this article
Cite this article as:
A.J. Manolis, L.E. Poulimenos, M.S. Kallistratos, I. Gavras and H. Gavras, Sympathetic Overactivity in Hypertension and Cardiovascular Disease, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990140
DOI https://dx.doi.org/10.2174/15701611113119990140 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 4
Current Pharmacogenomics New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension
Current Pharmaceutical Biotechnology Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation
Current Pharmaceutical Design The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective
Current Hypertension Reviews Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Vascular and Metabolic Actions of the Green Tea Polyphenol Epigallocatechin Gallate
Current Medicinal Chemistry Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Editorial [Hot Topic: Prebiotics and Probiotics: Delivering Therapeutics as Dietary Components (Executive Editor: Colum Dunne)]
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Current Neuropharmacology Adipose Tissue Quantification in Rats with the Use of Computed Tomography
Current Medical Imaging Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Atrial Conduction Disorders
Current Cardiology Reviews